Introduction
Von Willebrand disease (VWD) is a common coagulation disorder, with a reported prevalence ranging from 0.01% to 1%. 1, 2 Defects in von Willebrand factor (VWF) are associated clinically with a spectrum of bleeding symptoms, including easy bruising, menorrhagia, and epistaxis, with affected patients at increased risk for excessive bleeding with invasive procedures. Type 1 VWD is characterized by mild quantitative defects of VWF while type 3 VWD has virtually undetectable levels of VWF. The type 2 VWD variants are characterized by intrinsic functional defects, including defects in multimerization, platelet interactions, collagen binding, or factor VIII binding. 3 Although type 1 VWD accounts for the majority of cases, the relationship between VWF levels and clinical symptoms is not always clear, particularly with modest decreases in VWF. 3, 4 The International Society on Thrombosis and Haemostasis has recommended provisional criteria for the diagnosis of type 1 VWD, which include a personal history of bleeding symptoms, the presence of affected family members, and laboratory findings consistent with the diagnosis. 3 A panel of studies is recommended for workup of suspected VWD, including VWF antigen (VWF:Ag) as a measure of total VWF protein, and VWF ristocetin cofactor activity (VWF:RCo)
as a functional measure of VWF binding to platelets through their surface glycoprotein receptor GPIb. The VWF:RCo assay exploits the capacity of ristocetin to induce a conformational change in VWF that leads to VWF binding to platelet GPIb, but high variability and suboptimal sensitivity compromise the clinical utility of VWF:RCo. [5] [6] [7] Many factors can influence VWF levels. ABO blood group is a known modifier, with the lowest VWF levels present in those with VWD is characterized by a defective interaction between VWF and platelet GPIb in the absence of a significant defect in multimer structure. 3 Type 2M VWD is clinically suspected when the VWF:RCo/VWF:Ag ratio is decreased, and has also been linked to mutations in the A1
domain. [14] [15] [16] These mutations have been compiled online through the ISTH SSC VWF Online Database at www.vwf.group.shef.ac.uk. 17 In the local population of patients with VWD followed at the Comprehensive Center for Bleeding Disorders in Milwaukee, AA were overrepresented in the subgroup of VWD patients with type 2M VWD. The demographics of our type 1 VWD patients are similar to our overall patient population, with 7% identified as AA.
Our type 2M VWD patients, however, had a disproportionate number of AA, at 35%. Only 20%
of Caucasians in our population with type 2 VWD were categorized as 2M, while 80% of AA type 2 patients were classified as type 2M. 18 Many of the latter group, however, had minimal bleeding symptoms despite a significantly reduced VWF:RCo/VWF:Ag ratio. We noted that a group of single nucleotide polymorphisms (SNPs) in exon 28 appeared frequently in the African American controls. These findings suggested the hypothesis that common polymorphisms in the A1 loop of VWF might affect the ristocetin-based activity assay and therefore lead to altered 
DNA analysis
PCR amplification and semi-automated bidirectional sequencing using dye-terminator chemistry was performed using a set of primers designed specifically to amplify the entire coding sequence of VWF, including intron-exon boundaries, 3. 
Platelet aggregation studies
Platelet aggregation was performed in the BloodCenter of Wisconsin clinical hemostasis laboratory using fresh platelet rich plasma diluted to a platelet count of 300,000/μL. Ristocetin was added at concentrations ranging from 0.5 to 1.5 mg/mL and absorbance measured on a Chronolog platelet aggregometer (Havertown, PA) for a minimum of 5 minutes.
Botrocetin binding assay
Fixed lyophilized reconstituted platelets (Bio/data, Horsham, PA) were incubated with varying concentrations of botrocetin (0 to 1 mcg/mL) and plasma from AA subjects either homozygous for the 1472H allele or homozygous for the 1472D allele. After incubation for one hour, a polyclonal anti-VWF antibody (Dako) conjugated to Alexa Fluor 633 (Invitrogen) was added and fluorescence measured as previously described.
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GPIb complex binding assay
A construct containing full-length GPIbα was made with 2 gain-of-function mutations, G233V
and M239V, and expressed in HEK293T cells together with GPIbβ and GPIX to improve surface GPIb expression. Additional constructs were made containing a novel GPIbα mutation, D235Y, in combination with either G233V or M239V, as well as a construct containing all 3 mutations.
Constructs containing any 2 mutations demonstrated greater reactivity and the construct with DNA sequencing results revealed a trio of SNPs, I1380V, N1435S, and D1472H, that appeared frequently in the AA controls, but rarely in the Caucasian controls. Cloning of exon 28 from three of the AA subjects with the 3 SNPs demonstrated that these SNPs were present on the same allele for all three subjects (data not shown). I1380V is located in the middle of the A1 loop.
N1435S and D1472H are located just before and just after the C-terminal disulfide bond of the A1 loop (figure 2). This 3 SNP haplotype was present in 22% of the AA controls, as compared to only 3% of the Caucasian controls. An additional 39% of AA controls had the D1472H SNP alone. While 63% of the AA controls were positive for the D1472H SNP, only 17% of Caucasians had this SNP (p<0.001). The majority of the Caucasian controls (81%) had none of these SNPs (table 1) . No known type 2M mutations were observed in the control population.
The mean VWF:RCo/VWF:Ag ratio in AA subjects with the 3 SNP haplotype was 0.71, while the mean VWF:RCo/VWF:Ag ratio in AA subjects with only D1472H was 0.77 (p=NS). In contrast, the mean VWF:RCo/VWF:Ag ratio for the AA subjects with none of the SNPs in question was 0.91, significantly different from those with the 3 SNP haplotype and from those with D1472H alone (p<0.001).
Since the D1472H SNP appeared relatively frequently in both the AA and Caucasian controls, this SNP was investigated separately (figure 3A). The mean VWF:RCo/VWF:Ag ratio for AA with the D1472H SNP alone was 0.75, as compared to 0.91 for those without the SNP (p<0.001).
For the Caucasian controls, the mean VWF:RCo/VWF:Ag ratio for those with D1472H was 0.82, compared to a ratio of 0.97 for those without the SNP (p<0.001). There was no significant difference between AA and Caucasians with D1472H, nor was there a statistical difference between AA and Caucasians without D1472H. To confirm that these results were not simply due to the VWF:RCo assay used by our laboratory, samples with and without the D1472H polymorphism were sent to 5 North American laboratories. Similar results to those obtained in our laboratory were again observed, with the D1472H samples yielding a lower ratio than the samples without this polymorphism. The average ratio across the 5 laboratories (as normalized to an international standard) for subjects with D1472H was 0.80, while the average ratio for the subjects without D1472H was 0.95. It is important to note that 2 of these laboratories perform the VWF:RCo assay using a similar test protocol to ours, while 3 laboratories utilize platelet aggregometry instruments.
To determine if the apparent decrease in function was due to an isolated issue with the VWF:RCo assay, or an actual defect in VWF function, VWF:CB was examined. While the major binding site for collagen is located in the VWF A3 domain, there is a collagen binding site in the A1 domain that could potentially be disrupted by the D1472H polymorphism.
22 Previous work showed an elevation in VWF:CB, similar to that seen with VWF:Ag, when AA controls were compared to Caucasians. 11 When both AA and Caucasian controls from the ZPMCB-VWD were analyzed based on presence or absence of D1472H, no significant difference in VWF:CB/VWF:Ag ratio was seen ( figure 3B ). Therefore the D1472H polymorphism appears to have minimal effect on VWF-collagen interactions. Botrocetin was also tested as an additional method of inducing VWF-platelet interactions. When 6 subjects homozygous for the 1472H
allele were compared to 6 subjects homozygous for the 1472D allele, no difference was observed over a range of botrocetin concentrations (figure 4). When bleeding scores were examined, the mean for the AA subjects with D1472H was -0.49 (range -3 to 4), while the mean for AA without D1472H was 0.23 (range -2 to 4). Similar results were observed for the Caucasian controls. In general, a bleeding score ≥ 4 is considered significant. 19,23 Only 3 controls had a bleeding score > 4, all Caucasians without the D1472H polymorphism.
While none of the Caucasians were homozygous for D1472H, there were a number of AA subjects homozygous for this SNP, allowing analysis of copy number effect based on number of 1472H alleles (figure 5). The mean VWF:RCo/VWF:Ag ratio for the homozygous 1472H AA
For personal use only. on April 10, 2017. by guest www.bloodjournal.org From controls was 0.66, and the mean ratio for the heterozygous D1472H AA controls was 0.79 (p<0.01). When the heterozygous D1472H AA controls were compared to those homozygous for the wild-type sequence, there was also a significant difference (p<0.01). This suggests a dose effect of the 1472H variant in response to ristocetin in the AA population. Three of the AA controls had VWF:RCo/VWF:Ag ratios less than 0.5, and three more had ratios less than 0.6.
None of these 6 subjects had elevated bleeding scores, although their VWF:RCo/VWF:Ag ratios do fall into the range of type 2M VWD. This is important, as a ratio of less than 0.6 has been proposed as an indicator of type 2 VWD. 24, 25 The majority (60%) of subjects enrolled in the ZPMCB-VWD to date with a diagnosis of type 2M VWD had bleeding scores ≥ 4 (mean 4.4
with a range of -2 to 13).
Response to varying doses of ristocetin was assessed with platelet aggregation studies. Platelet rich plasma from a subject heterozygous for the D1472H polymorphism was compared to a wildtype subject at doses of ristocetin ranging from 0.5-1.5 mg/mL. A marked difference was observed (figure 6), with no aggregation at 0.8 mg/ml and delayed aggregation at 1 mg/mL for the D1472H subject compared to the normal control.
In the multiple linear regression analysis, the only significant finding was the presence of D1472H, after analysis for race, bleeding score, VWF:RCo/VWF:Ag ratio, and SNP status at I1380V, N1435S, and D1472H (p<0.005). Although there were only a small number of homozygous D1472H subjects in the sample (n=13), the genetic effect of the homozygous D1472H had slightly more than twice the effect on the ratio as the heterozygous (0.12 vs. 0.26, p<0.001). After accounting for the D1472H SNP, ethnicity had a marginal effect on the ratio
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To further investigate the effect of these polymorphisms on VWF-GPIb interactions independent of ristocetin, an assay was developed using GPIb mutations that allow spontaneous VWF binding even in the absence of ristocetin, referred to here as the GPIb complex binding assay. The VWF:RCo/VWF:Ag ratio obtained using the conventional ristocetin-based assay was compared to the GPIb complex binding/VWF:Ag ratio obtained with the new GPIb-VWF binding assay.
Another common polymorphism in the VWF A1 domain, A1381T, has been previously reported to affect VWF-GPIb interactions, causing an increased affinity for GPIb.
26 Therefore, we excluded those subjects with A1381T from analysis with our GPIb complex binding assay, leaving 37 AA and 30 Caucasian controls with GPIb complex binding results available for analysis.
Unlike the results obtained with VWF:RCo/Ag ratios, no racial difference was seen in the GPIb complex binding/VWF:Ag ratio. AA and Caucasian controls both had a mean GPIb complex binding/VWF:Ag ratio of 1.10 (p=NS). When subjects were divided according to race and SNP status at D1472H, no statistically significant difference in GPIb complex binding/VWF:Ag ratio was observed, suggesting that this assay is not affected by the presence of the D1472H polymorphism. AA controls with the polymorphism had a mean ratio of 1.06, while those without the polymorphism had a mean ratio of 1.
Caucasian controls with the polymorphism
For personal use only. on April 10, 2017. by guest www.bloodjournal.org From had a mean ratio of 1.13 while those without the polymorphism had a mean ratio of 1.08 (p=NS for all comparisons). Several subjects with published type 2M VWD mutations (Δ1392-1402, G1324S, I1425F) were tested using the GPIb complex binding assay and showed markedly reduced binding (data not shown), confirming that this assay is sensitive to VWF-GPIb interactions that might cause type 2M VWD. 
Discussion
Our results suggest that racial differences in VWF:RCo/VWF:Ag ratios are the result of increased frequency of the D1472H polymorphism in African Americans. This study is not the first to note racial differences in the dose response to added ristocetin. Ristocetin-induced platelet aggregation has been shown to be lower in AA as compared to Caucasians, particularly with lower concentrations of ristocetin.
27-29 AA had higher levels of VWF:Ag, with an associated decrease in the VWF:RCo/VWF:Ag ratio, and a similar increase in VWF collagen binding as compared to blood-type matched Caucasian controls. 11 We propose here that racial It is possible that the D1472H SNP decreases ristocetin-mediated VWF-GPIb interactions, through alteration of the ristocetin binding site on VWF. In support of this theory, control subjects in the ZPMCB-VWD study with D1472H had lower VWF:RCo/VWF:Ag ratios, on several occasions low enough to be considered for diagnosis of type 2M VWD, yet no increase in bleeding score was observed. In addition, two other SNPs in this region, I1380V and N1435S, were found to correlate with low VWF:RCo/VWF:Ag. These SNPs are linked to D1472H, and our data show that the latter SNP appears to predominate, as there is no significant difference between D1472H alone and the presence of the 3 SNPs together. The role of I1380V and N1435S remains undefined as we had no subjects with these SNPs in the absence of D1472H.
This relationship may reflect linkage with D1472H, or perhaps additional alterations in the A1 loop structure affecting ristocetin binding.
If the D1472H polymorphism affects in vitro ristocetin binding without affecting other VWF functions, other assays should show no difference between samples from subjects with and without this SNP. VWF:CB, when controlled for VWF:Ag, was not affected by D1472H SNP status; however, the collagen binding site is separate from the GPIb binding site. 30 The GPIb
For personal use only. on April 10, 2017. by guest www.bloodjournal.org From complex binding assay, however, provides another means of ristocetin-independent assessment of VWF-platelet interactions. There was no discernable difference in VWF-GPIb interactions, regardless of SNP status, as assessed by the GPIb complex binding assay, which measures platelet GPIb binding independent of ristocetin. Furthermore, binding was similar for subjects with and without D1472H, regardless of race, and no difference in the GPIb complex binding assay was seen for AA subjects with the 3 SNP haplotype as compared to those without the 3SNPs. These data suggest that the D1472H SNP may affect the VWF:RCo assay but might not cause a physiologically significant decrease in VWF function in vivo. Bleeding score data are entirely consistent with absence of physiologic consequences for the D1472H polymorphism.
Ristocetin causes enhanced platelet aggregation by inducing binding of VWF to platelet GPIb. However, the absence of thrombocytopenia and normal distribution of VWF multimers are noteworthy distinctions between the P1266L variant and patients with other type 2B associated mutations, such that one must wonder whether the results with ristocetin are of physiologic importance in this variant as well.
Given the wide range of VWF:Ag in the normal population, there is the potential for healthy individuals to have VWF:RCo levels low enough to merit a diagnosis of VWD. In the presence of specific SNPs, the VWF:RCo/VWF:Ag ratio may lead to the classification of the patient as VWD type 2M, when in reality, the discrepancy between VWF:RCo and VWF:Ag may be an artifact of the current functional assay. The recommended diagnostic criteria for VWD include bleeding symptoms in both the patient and in family members, as well as laboratory testing indicative of low VWF levels and/or lack of function of the VWF protein. 25 Reliance on the ristocetin cofactor activity assay, however, may be a source of diagnostic error in certain patients, especially those possessing SNPs that directly affect ristocetin's interactions with VWF.
In addition, presence of D1472H may affect ristocetin-induced platelet aggregation and could be 
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